Proficio Capital Partners LLC Purchases New Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Proficio Capital Partners LLC purchased a new stake in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 24,584 shares of the medical equipment provider's stock, valued at approximately $638,000. Proficio Capital Partners LLC owned approximately 0.05% of BioLife Solutions at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. D.A. Davidson & CO. raised its stake in shares of BioLife Solutions by 1.3% during the 4th quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider's stock worth $1,069,000 after buying an additional 519 shares during the period. Stifel Financial Corp lifted its holdings in BioLife Solutions by 5.4% during the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock valued at $325,000 after purchasing an additional 670 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of BioLife Solutions by 27.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after purchasing an additional 950 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions in the 4th quarter valued at $26,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new stake in BioLife Solutions during the 3rd quarter valued at about $28,000. 93.24% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other BioLife Solutions news, insider Sarah Aebersold sold 1,091 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the sale, the insider now directly owns 58,816 shares in the company, valued at $1,470,400. This trade represents a 1.82 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Troy Wichterman sold 987 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the transaction, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,117 shares of company stock valued at $534,442. 2.20% of the stock is owned by corporate insiders.

Remove Ads

BioLife Solutions Stock Up 2.6 %

Shares of NASDAQ:BLFS traded up $0.67 during mid-day trading on Thursday, hitting $26.17. 279,416 shares of the company traded hands, compared to its average volume of 348,880. The firm's 50 day simple moving average is $26.35 and its 200 day simple moving average is $25.52. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market cap of $1.23 billion, a P/E ratio of -24.69 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. On average, equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on BLFS. HC Wainwright boosted their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Benchmark reiterated a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp lifted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. StockNews.com upgraded shares of BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. Finally, Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.86.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.